3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Melanoma
25
Leukemia, Lymphocytic, Chronic, B-Cell
10
Breast Neoplasms
10
Recurrence
9
Leukemia, Myeloid, Acute
9
Carcinoma, Non-Small-Cell Lung
9
Neuroblastoma
8
Lymphoma, Non-Hodgkin
8
Neoplasms
7
Ovarian Neoplasms
6
Neoplasm Metastasis
6
Leukemia
6
Colorectal Neoplasms
6
Carcinoma, Renal Cell
6
Uveal Melanoma
5
Myelodysplastic Syndromes
5
Multiple Myeloma
5
Lymphoma, Follicular
5
Lymphoma
5
Lung Neoplasms
5
Head and Neck Neoplasms
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma, Mantle-Cell
4
Lymphoma, B-Cell, Marginal Zone
4
Lymphoma, B-Cell
4
Hematologic Neoplasms
4
Carcinoma, Squamous Cell
4
Carcinoma, Hepatocellular
4
Uterine Cervical Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
3
Interventions
Amifostine
4
Filgrastim
3
Cyclophosphamide
3
Melphalan
2
Irinotecan
2
Cytarabine
2
Carboplatin
2
spartalizumab
1
sodium thiosulfate
1
sargramostim
1
lometrexol
1
etoposide phosphate
1
Vincristine
1
Temozolomide
1
Sirolimus
1
Procarbazine
1
Phenobarbital
1
Peripheral Blood Stem Cell Transplantation
1
Paclitaxel
1
Mannitol
1
Lomustine
1
Interleukin-2
1
Idarubicin
1
Genetic Therapy
1
Gemcitabine
1
Folic Acid
1
Fibroblast Growth Factor 7
1
Fecal Microbiota Transplantation
1
Drug Therapy
1
Deoxycytidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Drug-Related Side Effects and Adverse Reactions
×
Interleukin-2
×
Clear all
NCT06302062
2024-12-03
TAL-T
Guangzhou FineImmune Biotechnology Co., LTD.
Phase 1
Recruiting
23 enrolled